Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Completed 3Terminated 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Colorectal Neoplasms 24Neoplasms 12Colonic Neoplasms 12Breast Neoplasms 12Prostatic Neoplasms 9Polycythemia Vera 9Venous Thromboembolism 8Multiple Myeloma 8Recurrence 5Rectal Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Thrombocythemia, Essential 4Ovarian Neoplasms 4Neoplasms, Plasma Cell 4Neoplasm Metastasis 4Myeloproliferative Disorders 4Barrett Esophagus 4Precancerous Conditions 3Melanoma 3Esophageal Neoplasms 3Adenomatous Polyps 3Adenoma 3Tobacco Use Disorder 2Thrombosis 2Thromboembolism 2Smoking Cessation 2Sarcoma 2Primary Myelofibrosis 2Neoplastic Cells, Circulating 2Neoplasms by Site 2

Interventions

Dexamethasone 110Cyclophosphamide 99Melphalan 91Bortezomib 68Peripheral Blood Stem Cell Transplantation 63Lenalidomide 57fludarabine phosphate 55Busulfan 53Filgrastim 50Antilymphocyte Serum 38Tacrolimus 37Thalidomide 36Radiotherapy 36Mycophenolic Acid 32fludarabine 28Cyclosporine 26Methotrexate 25Etoposide 22Calcium Dobesilate 22Prednisone 21Whole-Body Irradiation 20Methylprednisolone 20sargramostim 19pomalidomide 19Granulocyte Colony-Stimulating Factor 18carfilzomib 16daratumumab 15Cord Blood Stem Cell Transplantation 14Carmustine 14Rituximab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Neoplasms, Plasma Cell × Aspirin × Clear all
NCT00482261 2024-11-08

A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression

Peter MacCallum Cancer Centre, Australia

Phase 2 Completed
150 enrolled
Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT00790842 2018-10-24

PrE1003

PrECOG, LLC.

Phase 1/2 Terminated
63 enrolled 14 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01042704 2017-07-31

Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma

University of Pittsburgh

Phase 1 Completed
29 enrolled
Plasma cell

Neoplasms, Plasma Cell

NCT00258245 2013-04-29

Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

Barbara Ann Karmanos Cancer Institute

Phase 1 Completed
5 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡